David G. Maloney

Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

Retrieved on: 
Wednesday, May 19, 2021
Oncology, Health, Stem cells, Genetics, Clinical trials, Biotechnology, Branches of biology, Medical specialties, Biology, Stem cells, Transplantation medicine, Hematology, Surgical oncology, Lymphology, Hematopoietic stem cell, Myelodysplastic syndrome, Bone marrow, David G. Maloney, MDS and AML, JSP191, Jasper Therapeutics, MDS AND AML, JSP191, JASPER THERAPEUTICS

These data are consistent with pre-clinical work that demonstrated the capacity of JSP191 to target myelodysplastic cells and synergize with low doses of radiation.

Key Points: 
  • These data are consistent with pre-clinical work that demonstrated the capacity of JSP191 to target myelodysplastic cells and synergize with low doses of radiation.
  • \xe2\x80\x9cBased on this data and feedback from the FDA, we have now opened the dose-expansion phase of the study at the recommended Phase 2 dose.
  • JSP191, a first-in-class anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation.
  • In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.

Gamma Delta T Cell Cancer Therapy Market To Transform Cancer Immunotherapy Landscape

Retrieved on: 
Friday, April 23, 2021
Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, T cells, Immune system, Immunotherapy, Chimeric antigen receptor T cell, Bispecific monoclonal antibody, Gamma delta T cell, Active immunotherapy, David G. Maloney

b'Commercialization Market Potential After Market Launch: > USD 4 Billion\nGamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies\nIn recent times, cancer immunotherapies have become an appealing strategy among various different therapeutic options and have demonstrated its power against wide range of malignancies.

Key Points: 
  • b'Commercialization Market Potential After Market Launch: > USD 4 Billion\nGamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies\nIn recent times, cancer immunotherapies have become an appealing strategy among various different therapeutic options and have demonstrated its power against wide range of malignancies.
  • To overcome this, research is now focusing on exploiting rate type of gamma delta T cells in cancer immunotherapy.
  • Presently, researchers have designed gamma delta chimeric antigen receptor and bispecific antibodies targeting the gamma delta T cell to generate anti-tumor response in wide range of tumors.
  • Moreover, it is expected that coming years will witness a wide range of combinational therapy using gamma delta T cell therapy will emerge to manage the complexity of cancer.\nIt is expected that North America followed by Europe will dominate the global gamma delta T cell therapeutics market due to the high adoption rates of novel cancer immunotherapy in this region and the high prevalence of cancer.

Gamma Delta T Cell Cancer Therapy Market To Transform Cancer Immunotherapy Landscape

Retrieved on: 
Friday, April 23, 2021
Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, Immune system, Immunotherapy, Chimeric antigen receptor T cell, Bispecific monoclonal antibody, Active immunotherapy, David G. Maloney

b'- Gamma Delta T Cell Cancer Therapy to give New Horizon to Cancer Immunotherapy Market, Says Kuick Research\nCommercialization Market Potential After Market Launch: > USD 4 Billion\nGamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies\nIn recent times, cancer immunotherapies have become an appealing strategy among various different therapeutic options and have demonstrated its power against wide range of malignancies.

Key Points: 
  • b'- Gamma Delta T Cell Cancer Therapy to give New Horizon to Cancer Immunotherapy Market, Says Kuick Research\nCommercialization Market Potential After Market Launch: > USD 4 Billion\nGamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies\nIn recent times, cancer immunotherapies have become an appealing strategy among various different therapeutic options and have demonstrated its power against wide range of malignancies.
  • To overcome this, research is now focusing on exploiting rate type of gamma delta T cells in cancer immunotherapy.
  • Presently, researchers have designed gamma delta chimeric antigen receptor and bispecific antibodies targeting the gamma delta T cell to generate anti-tumor response in wide range of tumors.
  • Moreover, it is expected that coming years will witness a wide range of combinational therapy using gamma delta T cell therapy will emerge to manage the complexity of cancer.\nIt is expected that North America followed by Europe will dominate the global gamma delta T cell therapeutics market due to the high adoption rates of novel cancer immunotherapy in this region and the high prevalence of cancer.

Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

Retrieved on: 
Tuesday, January 19, 2021
Clinical medicine, Medicine, Medical specialties, Immune system, Lymphoma, Cancer immunotherapy, Lymphocytes, Natural killer cell, Chimeric antigen receptor T cell, Adoptive cell transfer, David G. Maloney

The primary objective of the study is to identify the maximum tolerated dose and any dose-limiting toxicities.

Key Points: 
  • The primary objective of the study is to identify the maximum tolerated dose and any dose-limiting toxicities.
  • PBCAR19B is a next-generation, stealth cell candidate for patients with CD19-positive malignancies such as relapsed/refractory Non-Hodgkin Lymphoma.
  • PBCAR19B is designed to improve the persistence of allogeneic CAR T cells following infusion by preventing rejection by T cells and natural killer (NK) cells.
  • Reducing or knocking down Class 1 expression on allogeneic CAR T cells has been shown to reduce CAR T cell killing by cytotoxic T cells.

Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

Retrieved on: 
Monday, December 21, 2020
Clinical medicine, Branches of biology, Medicine, Cancer immunotherapy, Cell biology, Biotechnology, Chimeric antigen receptor T cell, Immune system, Lymphoma, Immunotherapy, Cell therapy, David G. Maloney

The trial will enroll up to 30 patients and take place at City of Hope, where the chimeric antigen receptor T (CAR T) cell therapy was initially developed.

Key Points: 
  • The trial will enroll up to 30 patients and take place at City of Hope, where the chimeric antigen receptor T (CAR T) cell therapy was initially developed.
  • Lisa Feldman , M.D., Ph.D., a neurosurgeon and assistant clinical professor in the Division of Neurosurgery at City of Hope and principal investigator of the clinical trial, commented, Leptomeningeal brain tumors are a form of metastatic brain cancer, which is currently very difficult to treat.
  • We are encouraged by the potential of administering autologous IL13R2-CAR T cells intraventricularly to patients with leptomeningeal brain tumors.
  • Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy .

Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition

Retrieved on: 
Saturday, December 5, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Drug discovery, Life sciences, Health policy, Medicinal chemistry, Therapy, David G. Maloney, Melflufen, GDA-201, the NAM Therapeutic Platform, Gamida Cell

The data show that therapy using GDA-201 with monoclonal antibodies demonstrated significant clinical activity in heavily pretreated patients with advanced NHL.

Key Points: 
  • The data show that therapy using GDA-201 with monoclonal antibodies demonstrated significant clinical activity in heavily pretreated patients with advanced NHL.
  • Despite recent advancements in therapies for patients with hematologic malignancies, too many patients progress to develop refractory or resistant disease.
  • Preliminary results from this study were presented at the 2019 ASH Annual Meeting.
  • Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.

CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December

Retrieved on: 
Friday, November 20, 2020
Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Multiple myeloma, Monoclonal antibody therapy, Adoptive cell transfer, David G. Maloney

CT053 is an investigational anti-BCMA (B cell maturation antigen) autologous chimeric antigen receptor (CAR) T-cell product for the treatment of adult patients with relapsed and/or refractory multiple myeloma.

Key Points: 
  • CT053 is an investigational anti-BCMA (B cell maturation antigen) autologous chimeric antigen receptor (CAR) T-cell product for the treatment of adult patients with relapsed and/or refractory multiple myeloma.
  • These are open-label, multicenter studies evaluating the safety and efficacy of CT053 in adult patients with relapsed and/or refractory multiple myeloma.
  • CARsgen Therapeutics is a clinical-stage immuno-oncology company committed to the development of first-in-class and best-in-class CAR T-cell and antibody therapeutics.
  • CARsgen also has ongoing clinical CAR T-cell programs with a humanized CAR-CD19 for leukemia and lymphoma.

Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting

Retrieved on: 
Wednesday, November 4, 2020
Medical specialties, Clinical medicine, Medicine, Hematology, Pediatric cancers, Leukemia, PTPRC, Hematopoietic stem cell transplantation, Lymphoma, Hematologic disease, David G. Maloney, Acute myeloid leukemia

Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells.

Key Points: 
  • Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells.
  • A bone marrow transplant is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders.
  • Additional information on the Company's Phase 3 clinical trial in R/R AML can be found at sierratrial.com.
  • The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.

Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics Announce Investment to Advance Clinical Development of Natural Killer Cell Therapy

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Medical specialties, Health sciences, Medicine, Immune system, Immunology, Multiple myeloma, Natural killer cell, Monoclonal antibody, Therapy, David G. Maloney, MDX-1097, Indapta’s G-NK Cell Therapy, Indapta Therapeutics, The Multiple Myeloma Research Foundation, Myeloma Investment Fund

The Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics announced a partnership to support the advancement of the companys universal G-NK cell therapy into clinical trials for the treatment of patients with multiple myeloma.

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics announced a partnership to support the advancement of the companys universal G-NK cell therapy into clinical trials for the treatment of patients with multiple myeloma.
  • Indapta Therapeutics, Inc., is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcR-deficient natural killer (G-NK) cell therapy for the treatment of multiple cancers.
  • The collaboration is supported with an investment in Indapta by the MMRFs venture philanthropy arm, the Myeloma Investment Fund (MIF).
  • Indapta Therapeutics is developing a universal, allogeneic G-NK cell therapy designed to substantially improve the cytotoxicity of monoclonal antibody therapy in multiple cancers.

CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies

Retrieved on: 
Wednesday, October 21, 2020
Branches of biology, Clinical medicine, Medicine, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Lymphoblast, CD19, David G. Maloney

Additionally, one of these patients who had 30% lymphoblasts in the bone marrow achieved complete clearance after CTX110 infusion.

Key Points: 
  • Additionally, one of these patients who had 30% lymphoblasts in the bone marrow achieved complete clearance after CTX110 infusion.
  • CTX110, a wholly owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigative therapy targeting cluster of differentiation 19, or CD19.
  • The ongoing Phase 1 single-arm, multi-center, open label clinical trial, CARBON, is designed to assess the safety and efficacy of several dose levels of CTX110 for the treatment of relapsed or refractory B-cell malignancies.
  • CRISPR THERAPEUTICSstandard character mark and design logo, CTX110, CTX120, and CTX130 are trademarks and registered trademarks ofCRISPR Therapeutics AG.